Efficacy and Safety of Garsorasib in the Treatment of Patients With KRASG12C-Mutated Non–Small Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
Lancet Respir Med 2024 Jun 10;[EPub Ahead of Print], Z Li, X Dang, D Huang, S Jin, W Li, J Shi, X Wang, Y Zhang, Z Song, J Zhang, W Zhuang, X Liu, L Jiang, X Meng, M Zhao, J Zhou, L Zhang, P Wang, H Luo, J Yang, S Cang, X Wang, L Zhang, S LuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.